Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Collaboration › Details

Affimed–Morgan Stanley: investor conference, 202209 supply service Affimed to participate in Morgan Stanley Annual Global Healthcare Conference 2022


Period Period 2022-09-12 � 2022-09-14
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st Affimed N.V. (Nasdaq: AFMD)
  Group Affimed (Group)
  Partner, 2nd Morgan Stanley & Co. LLC
  Group Morgan Stanley (Group)
Product Product Morgan Stanley Global Healthcare Conference 2022 New York

Affimed N.V.. (9/1/22). "Press Release: Affimed to Present at Upcoming Investor Conferences". Heidelberg.

Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of September 2022.

2022 Wells Fargo Healthcare Conference (September 6-9, 2022)
Date: Wednesday, September 7, 2022
Presentation Time: 3:10 p.m. Eastern Daylight Time
Location: Boston, MA

Citi’s 17th Annual BioPharma Virtual Conference (September 6-8, 2022)
Date: Thursday, September 8, 2022
Only one-on-one meetings
Location: Boston, MA

Morgan Stanley’s 20th Annual Global Healthcare Conference (September 12-14, 2022)
Date: Tuesday, September 13, 2022
Only one-on-one meetings
Location: New York, NY

Jefferies Cell and Genetic Medicine Summit (September 29-30, 2022)
Date: Thursday, September 29, 2022
Only one-on-one meetings
Location: New York, NY

For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your event representative or Alex Fudukidis via email at or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit

Affimed Investor Contact

Alexander Fudukidis
Director, Investor Relations
Tel.: +1 (917) 436-8102

Record changed: 2022-09-06


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Affimed (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top